Cost-Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer with Different PD-L1 Expression Levels

Xiuhua Weng, Shaohong Luo, Shen Lin, Lixian Zhong, Meiyue Li, Rao Xin, Pinfang Huang, Xiongwei Xu

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Fingerprint

Dive into the research topics of 'Cost-Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer with Different PD-L1 Expression Levels'. Together they form a unique fingerprint.

Medicine & Life Sciences